What changed from existing technology?
This study looks at how to combine different types of evidence and do studies that connect different medical devices, especially those that are high-risk or new, to help make better decisions about their use.
The study identifies new approaches for integrating different types of evidence and conducting bridging studies for high-risk and innovative medical devices, which are not commonly addressed in traditional clinical evaluation methods.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
or conventional clinical evaluation because randomized clinical trials may be difficult to conduct. As a result, methodologies for integrating heterogeneous evidenc
Abstract ↗OpenAlex author affiliations: Eskom (South Africa)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The methodologies identified in this study could support regulatory decision-making and health technology evaluation for high-risk and innovative medical devices, especially when traditional clinical trials are not feasible.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchEvidence integration and bridging methodologies for high-risk and innovative medical devices and in vitro diagnostic medical devices: a scoping reviewFrontiers in Medicine · Published 2026-08-28 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.